MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

09 Mar 2022 15:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

24 Feb 2022 07:00:02 By Nasdaq GlobeNewswire

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

31 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st

30 Jan 2022 15:00:00 By Nasdaq GlobeNewswire

Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer

10 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

30 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

23 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021

12 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results

04 Nov 2021 05:50:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

04 Oct 2021 05:50:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update

05 Aug 2021 05:50:00 By Nasdaq GlobeNewswire